Drug Profile
Ertugliflozin/metformin - Merck/Pfizer
Alternative Names: MK 8835/metformin; MK 8835B; SEGLUROMETLatest Information Update: 18 Mar 2022
Price :
$50
*
At a glance
- Originator Merck & Co; Pfizer
- Class Antihyperglycaemics; Biguanides; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 16 Feb 2022 No development reported - Phase-III for Type 2 diabetes mellitus (Adjunctive treatment) in Ukraine, South Korea, Israel, Russia, Philippines, Canada, Argentina, Georgia, Colombia, Hong Kong, Mexico, New Zealand, Serbia, South Africa, Thailand, Turkey (PO)
- 27 Dec 2019 Merck & Co and Pfizer completes the VERTIS-CV phase III in Type-2 diabetes mellitus (Adjunctive treatment) in the US, the UK, Ukraine, Turkey, Thailand, South Africa, Slovakia, Serbia, Romania, Poland, New Zealand, Netherlands, Mexico, Lithuania, Latvia, Hungary, Hong Kong, Greece, Georgia, Czech Republic, Colombia, Bulgaria and Argentina (NCT01986881)
- 01 Mar 2018 Registered for Type-2 diabetes mellitus in European Union, Norway, Iceland and Liechtenstein (PO)